YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma

EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth

(2010) F. Bouchard et al.   BLOOD

Matrix Metalloproteinase-9 Regulates Tumor Cell Invasion through Cleavage of Protease Nexin-1

(2010) D. Xu et al.   CANCER RESEARCH

Differential gene expression in central nervous system lymphoma

(2009) J. L. Rubenstein et al.   BLOOD

Plasma YKL-40: a potential new cancer biomarker?

(2009) Julia S Johansen et al.   Future Oncology

Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer

(2009) Roopali Roy et al.   JOURNAL OF CLINICAL ONCOLOGY

Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas

(2009) Helene F. S. Negaard et al.   LEUKEMIA & LYMPHOMA

Pathway analysis of primary central nervous system lymphoma

(2008) H. W. Tun et al.   BLOOD

Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas

(2008) Manabu Kinoshita et al.   Brain Tumor Pathology

Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects

(2008) J. S. Johansen et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Insights into the biology of primary central nervous system lymphoma

(2008) Maciej M. Mrugala et al.   Current Oncology Reports

Protein Biomarker Identification in the CSF of Patients With CNS Lymphoma

(2007) Sushmita Roy et al.   JOURNAL OF CLINICAL ONCOLOGY